Filing Flows › Bioadaptives (BDPT) › Q2 2025
Bioadaptives (BDPT) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 14, 2025
Bioadaptives (BDPT) reported revenue of $3K for the second quarter 2025 (Q2 2025), +377% from a year earlier.
Bioadaptives, Q2 2025: revenue $3K (+377% year over year), net loss $552K, operating cash flow −$111K. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $3K | — | +377% |
| Operating profit | −$279K | — | — |
| Net earnings | −$552K | — | — |
| Operating cash flow | −$111K | — | — |
What changed
Revenue was $3K in Q2 2025, up 377% year over year.
Gross margin was 33.0%, down 30.5 points from a year earlier. Operating costs exceeded revenue by $279K, an operating margin of -8674.1%. Operating expenses grew 200% against revenue growth of 377%. The fastest-growing cost line was General & admin (+4186%). The quarter ended with a net loss of $552K. Minority interests bore $394K of it: to shareholders the quarter was a loss of $158K. Non-operating items added $121K, -77% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$111K. Non-cash charges added back $1K of depreciation and amortization and $29K of share-based compensation. Working capital and other items added $412K.
Questions
What was Bioadaptives' revenue in the second quarter 2025?
Bioadaptives (BDPT) reported revenue of $3K for the second quarter 2025 (Q2 2025), +377% from a year earlier.
Source: Bioadaptives 10-Q on SEC EDGAR.